申请人:Guangzhou Henovcom Bioscience Co., Ltd
公开号:EP3674289A1
公开(公告)日:2020-07-01
Provided are a long-acting prodrug of Rasagiline, preparation method and use thereof. The long-acting prodrug of Rasagiline has a structure of formula (I), wherein T is absent, or T is selected from (II); each of R1 and R2 is independently selected from H, D, and alkyl; W is absent, or W is selected from (CH2)n, wherein n is an integer selected from 1 to 15; X is absent, or X is selected from (CH2)m, wherein m is an integer selected from 1 to 10; Y is absent, or Y is selected from -C(=O)NH-, -NHC(=O)-; R3 is selected from substituted or unsubstituted C1-C30 alkyl, substituted or unsubstituted C2-C30 alkenyl, substituted or unsubstituted C2-C30 alkynyl, substituted or unsubstituted C3-C30 cycloalkyl, cholane aliphatic group, -R3a-C(=O)O-R3b, -R3a-OC(=O)-R3b, -R3a-C(=O)NH-R3b, -R3a-NHC(=O)-R3b, -R3a-S(=O)1-2O-R3b and -R3a-OS(=O)1-2-R3b. The provided prodrug of Rasagiline has a high melting point and low solubility, and it can form a drug reservoir in the body after being administered if it is made in a form of injection, prolonging the release rate of the prodrug in the body and achieving an effect of long-acting treatment.
提供了拉沙吉林的长效前药、制备方法及其用途。拉沙吉林的长效前药具有如下结构式(I),其中T为空缺,或T选自(II);R1和R2中的每一个独立选自H、D和烷基;W为空缺,或W选自(CH2)n,其中n为1至15之间的整数;X为空缺,或X选自(CH2)m,其中m为1至10之间的整数;Y为空缺,或Y选自-C(=O)NH-、-NHC(=O)-;R3选自取代或未取代的C1-C30烷基、取代或未取代的C2-C30烯基、取代或未取代的C2-C30炔基、取代或未取代的C3-C30环烷基、胆烷脂肪基、-R3a-C(=O)O-R3b、-R3a-OC(=O)-R3b、-R3a-C(=O)NH-R3b、-R3a-NHC(=O)-R3b、-R3a-S(=O)1-2O-R3b和-R3a-OS(=O)1-2-R3b。所提供的拉沙吉林前药具有高熔点和低溶解度,如果以注射剂形式制备,则可在体内形成药物储库,延长前药在体内的释放速率,达到长效治疗的效果。